NCT02378870View on ClinicalTrials.gov

A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Osteodex

Osteodex 3.0 mg/kg given every two week, maximum 13 times.

DRUG

Placebo

Trial Locations (1)

901 85

Oncology clinic, Norrlands Universitetssjukhus, Umeå

Sponsors

Lead Sponsor

DexTech Medical AB
All Listed Sponsors
lead

DexTech Medical AB

INDUSTRY

NCT02378870 - A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC | Biotech Hunter | Biotech Hunter